Episode 186 - June 12, 2026

Biotech market performance remains resilient, with the XBI index outperforming the S&P 500 year-to-date despite recent volatility. The IPO landscape shows signs of recovery, characterized by high-quality, data-driven offerings and a growing trend of dual-track processes where private companies weigh public listings against potential acquisitions. Large-cap pharmaceutical companies are aggressively pursuing oncology assets, evidenced by significant transactions such as GSK’s $11 billion acquisition of Nuvalent and Incyte’s purchase of Vega. Clinical developments continue to drive sector sentiment, particularly in the RAS inhibition space, where combination therapies like Tango’s PRMT5 inhibitor and Revolution Medicines’ RAS inhibitors demonstrate unprecedented response rates in pancreatic cancer. Meanwhile, regulatory scrutiny remains a critical factor for gene therapy programs, as companies navigate complex clinical milestones and shifting FDA expectations for rare disease treatments.